Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Microbiol Spectr ; 10(1): e0153221, 2022 02 23.
Artículo en Inglés | MEDLINE | ID: mdl-34985301

RESUMEN

COVID-19 vaccination has proven to be effective at preventing symptomatic disease but there are scarce data to fully understand whether vaccinated individuals can still behave as SARS-CoV-2 transmission vectors. Based on viral genome sequencing and detailed epidemiological interviews, we report a nosocomial transmission event involving two vaccinated health care-workers (HCWs) and four patients, one of them with fatal outcome. Strict transmission control measures, as during the prevaccination period, must be kept between HCWs and HCWs-patients in nosocomial settings. IMPORTANCE COVID-19 vaccination has proven to be effective at preventing symptomatic disease. Although some transmission events involving vaccinated cases have also been reported, scarce information is still available to fully understand whether vaccinated individuals may still behave as vectors in SARS-CoV-2 transmission events. Here, we report a SARS-CoV-2 nosocomial transmission event, supported on whole genome sequencing, in early March 2021 involving two vaccinated HCWs and four patients in our institution. Strict transmission control measures between HCWs and HCWs - patients in nosocomial settings must not be relaxed, and should be kept as strictly as during the prevaccination period.


Asunto(s)
Vacunas contra la COVID-19/administración & dosificación , COVID-19/prevención & control , Infección Hospitalaria/transmisión , SARS-CoV-2/inmunología , COVID-19/transmisión , COVID-19/virología , Infección Hospitalaria/epidemiología , Infección Hospitalaria/prevención & control , Infección Hospitalaria/virología , Personal de Salud/estadística & datos numéricos , Humanos , Filogenia , SARS-CoV-2/clasificación , SARS-CoV-2/genética , SARS-CoV-2/aislamiento & purificación , Vacunación , Secuenciación Completa del Genoma
2.
mSphere ; 6(4): e0038921, 2021 08 25.
Artículo en Inglés | MEDLINE | ID: mdl-34346709

RESUMEN

SARS-CoV-2 nosocomial outbreaks in the first COVID-19 wave were likely associated with a shortage of personal protective equipment and scarce indications on control measures. Having covered these limitations, updates on current SARS-CoV-2 nosocomial outbreaks are required. We carried out an in-depth analysis of a 27-day nosocomial outbreak in a gastroenterology ward in our hospital, potentially involving 15 patients and 3 health care workers. Patients had stayed in one of three neighboring rooms in the ward. The severity of the infections in six of the cases and a high fatality rate made the clinicians suspect the possible involvement of a single virulent strain persisting in those rooms. Whole-genome sequencing (WGS) of the strains from 12 patients and 1 health care worker revealed an unexpected complexity. Five different SARS-CoV-2 strains were identified, two infecting a single patient each, ruling out their relationship with the outbreak; the remaining three strains were involved in three independent, overlapping, limited transmission clusters with three, three, and five cases. Whole-genome sequencing was key to understand the complexity of this outbreak. IMPORTANCE We report a complex epidemiological scenario of a nosocomial COVID-19 outbreak in the second wave, based on WGS analysis. Initially, standard epidemiological findings led to the assumption of a homogeneous outbreak caused by a single SARS-CoV-2 strain. The discriminatory power of WGS offered a strikingly different perspective consisting of five introductions of different strains, with only half of them causing secondary cases in three independent overlapping clusters. Our study exemplifies how complex the SARS-CoV-2 transmission in the nosocomial setting during the second COVID-19 wave occurred and leads to extending the analysis of outbreaks beyond the initial epidemiological assumptions.


Asunto(s)
COVID-19/epidemiología , COVID-19/transmisión , Infección Hospitalaria/epidemiología , Infección Hospitalaria/transmisión , SARS-CoV-2/patogenicidad , Adolescente , Adulto , Anciano , COVID-19/virología , Infección Hospitalaria/virología , Brotes de Enfermedades/prevención & control , Femenino , Genoma Viral/genética , Personal de Salud , Hospitales , Humanos , Masculino , Persona de Mediana Edad , Filogenia , SARS-CoV-2/genética , Secuenciación Completa del Genoma/métodos , Adulto Joven
3.
3D Print Med ; 7(1): 11, 2021 Apr 22.
Artículo en Inglés | MEDLINE | ID: mdl-33890198

RESUMEN

BACKGROUND: The integration of 3D printing technology in hospitals is evolving toward production models such as point-of-care manufacturing. This study aims to present the results of the integration of 3D printing technology in a manufacturing university hospital. METHODS: Observational, descriptive, retrospective, and monocentric study of 907 instances of 3D printing from November 2015 to March 2020. Variables such as product type, utility, time, or manufacturing materials were analyzed. RESULTS: Orthopedic Surgery and Traumatology, Oral and Maxillofacial Surgery, and Gynecology and Obstetrics are the medical specialties that have manufactured the largest number of processes. Working and printing time, as well as the amount of printing material, is different for different types of products and input data. The most common printing material was polylactic acid, although biocompatible resin was introduced to produce surgical guides. In addition, the hospital has worked on the co-design of custom-made implants with manufacturing companies and has also participated in tissue bio-printing projects. CONCLUSIONS: The integration of 3D printing in a university hospital allows identifying the conceptual evolution to "point-of-care manufacturing."

4.
JCI Insight ; 5(15)2020 08 06.
Artículo en Inglés | MEDLINE | ID: mdl-32759499

RESUMEN

Platinum-based chemotherapy in combination with immune-checkpoint inhibitors is the current standard of care for patients with advanced lung adenocarcinoma (LUAD). However, tumor progression evolves in most cases. Therefore, predictive biomarkers are needed for better patient stratification and for the identification of new therapeutic strategies, including enhancing the efficacy of chemotoxic agents. Here, we hypothesized that discoidin domain receptor 1 (DDR1) may be both a predictive factor for chemoresistance in patients with LUAD and a potential target positively selected in resistant cells. By using biopsies from patients with LUAD, KRAS-mutant LUAD cell lines, and in vivo genetically engineered KRAS-driven mouse models, we evaluated the role of DDR1 in the context of chemotherapy treatment. We found that DDR1 is upregulated during chemotherapy both in vitro and in vivo. Moreover, analysis of a cohort of patients with LUAD suggested that high DDR1 levels in pretreatment biopsies correlated with poor response to chemotherapy. Additionally, we showed that combining DDR1 inhibition with chemotherapy prompted a synergistic therapeutic effect and enhanced cell death of KRAS-mutant tumors in vivo. Collectively, this study suggests a potential role for DDR1 as both a predictive and prognostic biomarker, potentially improving the chemotherapy response of patients with LUAD.


Asunto(s)
Adenocarcinoma del Pulmón/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Receptor con Dominio Discoidina 1/antagonistas & inhibidores , Resistencia a Antineoplásicos , Neoplasias Pulmonares/tratamiento farmacológico , Mutación , Proteínas Proto-Oncogénicas p21(ras)/genética , Adenocarcinoma del Pulmón/genética , Adenocarcinoma del Pulmón/metabolismo , Adenocarcinoma del Pulmón/patología , Animales , Apoptosis , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/metabolismo , Movimiento Celular , Proliferación Celular , Cisplatino/administración & dosificación , Receptor con Dominio Discoidina 1/genética , Receptor con Dominio Discoidina 1/metabolismo , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patología , Ratones , Paclitaxel/administración & dosificación , Células Tumorales Cultivadas , Ensayos Antitumor por Modelo de Xenoinjerto
5.
Rev. calid. asist ; 22(5): 243-248, sept. 2007. ilus, tab
Artículo en Es | IBECS | ID: ibc-058163

RESUMEN

Objetivos: Evaluar la vía clínica (VC) de la colecistectomía laparoscópica (CL) tras un año de su implantación. Material y método: El 1 de febrero 2005 se implantó en nuestro servicio la VC de la colecistectomía laparoscópica. Se ha estudiado a todos los pacientes incluidos en la vía clínica desde su puesta en marcha. Los criterios de evaluación incluyen el grado de cumplimiento, los indicadores de efectividad en la atención clínica, el impacto económico y los indicadores de satisfacción basados en la encuesta. Los resultados se comparan con los de una serie de pacientes intervenidos durante el año anterior (2004) a la implantación de la VC. Resultados: Se ha revisado una serie de 170 pacientes intervenidos durante el año anterior a la puesta en marcha de la vía clínica, 136 mujeres y 34 varones con una media de edad de 51 años. La estancia media y el gasto medio del proceso de estos pacientes fueron de 1,29 días y 1.354 euros, respectivamente. Durante un año tras la implantación de la VC se realizaron 170 colecistectomías laparoscópicas, que se incluyeron en el estudio, a 133 mujeres y 37 varones con una media de edad de 50 años. La estancia media de estos pacientes fue de 1,28 días y el gasto medio por proceso, 1.334,7 euros. El grado de cumplimiento de la estancia fue del 85,3%. El grado de satisfacción fue del 96,8%. Conclusiones: El estudio muestra que la estancia media y el gasto medio por proceso han disminuido tras la implantación de la VC y con un alto grado de satisfacción de los pacientes


Objectives: To evaluate a clinical pathway for laparoscopic cholecystectomy 1 year after its introduction. Material and method: A clinical pathway for laparoscopic cholecystectomy was introduced in our service on 1st February, 2005. All patients included in the clinical pathway after its introduction were studied. The evaluation criteria included the degree of compliance, indicators of the effectiveness of clinical care, economic impact, and indicators of satisfaction based on a survey. The results were compared with those obtained in a series of patients who underwent surgery during the year before the introduction of the clinical pathway (2004). Results: A series of 170 patients who underwent surgery in the year prior to the introduction of the clinical pathway was evaluated (136 women and 43 men). The mean age was 51 years. In these patients, the mean length of hospital stay was 1.29 days and the mean cost of the process was 1,354 euros. In the first year after the introduction of the clinical pathway, 170 laparoscopic cholecystectomies were performed and included in this study. There were 133 women and 37 men. The mean age of these patients was 50 years. The mean length of hospital stay was 1.28 days and the mean cost in patients included in the clinical pathway was 1,334.7 euros. The degree of compliance with length of hospital stay was 85.3%. The degree of satisfaction was 96.8%. Conclusions: The mean length of hospital stay and the mean cost per process decreased after the creation of the clinical pathway. Patient satisfaction was high


Asunto(s)
Masculino , Femenino , Persona de Mediana Edad , Humanos , Colecistectomía Laparoscópica/métodos , Colecistectomía Laparoscópica/normas , Protocolos Clínicos , Costos de la Atención en Salud , Satisfacción del Paciente , Tiempo de Internación , Proyectos Piloto , España
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...